All News

Article

Year of the Wolf: Lupus at EULAR2020

Kathryn H. Dao, M.D.

For a disease that has been recognized since the days of Hippocrates, we are finally making some progress towards understanding systemic lupus erythematosus (SLE) and how to tame the wolf.  Listed below are the top 5 studies and their summaries presented at the recent EULAR e-Congress confer

Olga Petryna Tweet
DrPetryna
How do you approach your PsA patients with suboptimal response to MTX in moderate doses?
Olga Petryna Tweet
DrPetryna
#EULAR2020 #op0050 RCT ph4 results: in inadequately controlled PsA addition of ADA results in better outcomes in terms MDA, ACR20, PASI75, HAQ-DI&LEI as opposed to MTX dose escalation @RheumNow https://t.co/iMgCkRawCl
Olga Petryna Tweet
DrPetryna
#EULAR2020 #LB0001 SELECT-PsA-1 Upadacitinib vs PBO vs ADA: UPA 15/30 mg non-inferior &UPA 30 superior to ADA for ACR20. At wk12 ACR 20 70.6% UPA15, 78.5% UPA30 vs 36.2%PBO & 65%ADA. Better ACR50/70 &MDA va PBO. No new safety signals. @RheumNow https://t.co/QZkMdoqXEC
Olga Petryna Tweet
DrPetryna
#eular2020 #op0205 phase 1 trial of novel URAT1 inhibitor D-0120 in healthy adults: safe up to 20 mg/d after 7 days. Significant reduction of sUA peaks at 4-8h & lasts up to 24h @RheumNow
Olga Petryna Tweet
DrPetryna
#EULAR2020 #op0106 Cosentyx 150mg demonstrates clinical improvement in NrAxSpA Sx in Ph3 PREVENT 52wk study. Significant improvement in ASAS40, BASDAI50& ASdAS-CRP ID. MRI BME score significantly decreased (-1.68&-1.03 (no LD) vs -0.39 PBO) @RheumNow https://t.co/UX7mkJ8qMJ
Olga Petryna Tweet
DrPetryna
#eular2020 #op0227 52 wk SEC vs ADA H2H EXCEED trial: Acr20 67.4%SEC vs 61.5%ADA. Better retention of SEC at 85.7% vs 76.3%ADA. SEC significantly outperforms in PASI90 (65.4 SEC be 43.2 ADA) @RheumNow https://t.co/M8UGydTFDF
Olga Petryna Tweet
DrPetryna
EULAR2020 #op0168 🇰🇷Population-based cohort study identifies both allopurinol& febuxostat associated with MI, cerebral infarction&cerebral hemorrhage. Fluctuation of sUA&potentially even cardiovascular gout attacks (urate crystals in vasculature) as possible causes @RheumNow https://t.co/mcb5NLnMq1
Olga Petryna Tweet
DrPetryna
#EULAR2020 #op0028 12 wk ph3 RELIEF study: Apremilast effectively relieves OU pain and OU number after 12 wks of 30 mg bid Rx. Great proportion of APR PTs achieved >10 mm &>30 mm improvement in OU pain @RheumNow https://t.co/p71sz9XL0e
David Liew Tweet
drdavidliew
Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis? @Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats) Something to consider in these difficult-to-treat pts? @LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow https://t.co/XpffkDNqhU
David Liew Tweet
drdavidliew
For patients on bDMARDs having surgery, we worry about post-op delayed wound healing. In this Japanese cohort, TCZ use was a risk factor. Unclear if meds withheld, but given IL-6 upreg in wound healing, it's plausible TCZ might have worse outcomes?? SAT0047 #EULAR2020 @RheumNow https://t.co/HVIKPplwiA
Janet Pope Tweet
Janetbirdope
What dose/frequency of rituximab do you use in maintenance ANCA #vasculitis? @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020
k dao Tweet
KDAO2011
#EULAR2020 THU0260 LESS IS BEST when it comes to steroids: Singapore 10 yr retrospect SLE study noted GCs dose is an independent predictor of mortality for hospitalized infection even when adjusted for disease activity.
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×